NDAINJECTIONINJECTABLE
Approved
Dec 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
COGENTIN (benztropine mesylate) by Molecular Devices is clinical pharmacology benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. First approved in 1959.
Drug data last refreshed 8h ago · AI intelligence enriched 1w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
COGENTIN (benztropine mesylate) is an anticholinergic agent with antihistaminic properties approved in 1959 for the management of parkinsonism. It works by blocking cholinergic activity in the central nervous system, alleviating motor symptoms associated with Parkinson's disease. The drug is administered via injection and represents a legacy therapeutic approach to extrapyramidal symptoms.
LOE Approaching
This legacy injectable faces LOE pressure with 30% competitive intensity; brand teams are typically lean and focused on defensive positioning rather than growth initiatives.
Mechanism of Action
CLINICAL PHARMACOLOGY Benztropine mesylate possesses both anticholinergic and antihistaminic effects, although only the former have been established as therapeutically significant in the management of parkinsonism. In the isolated guinea pig ileum, the anticholinergic activity of this drug is about…
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on COGENTIN as a pharma professional means joining a team managing a legacy product through LOE with minimal hiring and limited growth opportunity. Career advancement likely requires transition to newer pipeline assets or lateral moves, as the product itself offers defensive rather than innovative career development.
Brand Manager
Worked on COGENTIN at Molecular Devices? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.